← Back to Search

Monoclonal Antibodies

FT516 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Fate Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 15 years

Awards & highlights

Study Summary

This trial is testing a new drug, FT-516, to see if it works well with monoclonal antibodies to treat advanced solid tumors. The study will have two parts: first they will test different doses of FT-516 to see what is safe and effective, then they will enroll people into specific groups to test the drug further.

Eligible Conditions

Solid Tumors, Adult

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Dose-Limiting Toxicities (DLTs) Within Each Dose Level Cohort

Severity of DLTs Within Each Dose Level Cohort

Secondary outcome measures

Determination of PK of FT516 in peripheral blood

Disease Control Rate (DCR)

Investigator-Assessed Duration of Response (DOR)

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: FT516 in combination with avelumabExperimental Treatment5 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cyclophosphamide

1995

Completed Phase 3

~3770

FT516

2020

Completed Phase 1

~10

Fludarabine

2012

Completed Phase 3

~1100

Avelumab

2018

Completed Phase 2

~2450

IL-2

2007

Completed Phase 4

~1180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Fate TherapeuticsLead Sponsor

21 Previous Clinical Trials

1,789 Total Patients Enrolled

Fate Trial DisclosureStudy DirectorFate Therapeutics

10 Previous Clinical Trials

854 Total Patients Enrolled

Jeff Chou, MDStudy DirectorFate Therapeutics

4 Previous Clinical Trials

106 Total Patients Enrolled

Media Library

Avelumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04551885 — Phase 1

Solid Tumors Research Study Groups: FT516 in combination with avelumab

Solid Tumors Clinical Trial 2023: Avelumab Highlights & Side Effects. Trial Name: NCT04551885 — Phase 1

Avelumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04551885 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any precedents of FT516 being utilized in previous clinical investigations?

"Currently, there are 1018 ongoing clinical trials exploring FT516 with 173 of them in Phase 3. Among the many locations hosting these studies is Philadelphia, Pennsylvania - although they total 32342 sites worldwide."

Answered by AI

How many participants has the trial recruited thus far?

"Currently, this research is not in the process of recruiting. Initially posted on September 7th 2020 and recently edited on November 11 2021, it has since become inactive. However, there are 2425 trials involving cancer patients and 1018 for FT516 which remain open to applicants."

Answered by AI

To what maladies is FT516 commonly prescribed?

"FT516 is an effective treatment for a range of diseases, such as multiple sclerosis and leukemia. It has also proven to be beneficial in addressing myelocytic, acute, retinoblastoma, and histiocytic lymphomas."

Answered by AI

How reliable is FT516 for mitigating health risks to individuals?

"Due to the limited data available on FT516's safety and efficacy, it earned a score of 1 out of 3 in our team at Power's assessment."

Answered by AI

Is enrollment open for this research endeavor?

"Currently, this clinical trial is no longer searching for volunteers. It was first announced on September 7th 2020 and the latest update occurred November 11th 2021. For those looking for similar studies, 2425 cancer-related trials are currently enrolling patients while FT516 has 1018 active recruitment phases."

Answered by AI

Recent research and studies

BloodJournal

Pluripotent Stem Cell–derived NK Cells with High-affinity Noncleavable Cd16a Mediate Improved Antitumor Activity

Zhu, Huang, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, et al.. 2020. “Pluripotent Stem Cell–derived NK Cells with High-affinity Noncleavable Cd16a Mediate Improved Antitumor Activity”. Blood. American Society of Hematology. doi:10.1182/blood.2019000621.

clinicaltrials.govStudy

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

2020. "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04551885.